Lambda Biologics enables the robust evaluation of complex therapeutic modalities by offering optimized preclinical models for antibody-drug conjugates (ADCs) and bispecific antibodies that are aligned with the latest FDA and EMA regulatory expectations.
* Benefits of Human Organoid-based platform compared with traditional cell-lines or animal model for ADC development
Target expression was evaluated by flow cytometry in 10 CRC, 9 LC, and 9 PC lines.
The graphs summarize expression levels by cancer type and demonstrate heterogeneous expression across lines.
Specialized organoid-based assays for modeling human biology in vitro—designed to enhance predictive accuracy in drug response, toxicity, and disease progression.
Custom in vitro studies leveraging organoid and cell-based models to support hypothesis-driven research, mechanistic validation, and translational insights.
Advanced analytical support including molecular profiling, spatial biology, and imaging—enabling precise characterization of organoid and cell-based systems.
